Who we are
Back
Who we are
About Fermion
Management
Facilities
Quality management
Sustainability
Fermion's history
Brochures and articles
News
Generic API
Back
Generic API
About Generic API
API List
Intermediate List
Material Safety Data Sheets
Standard packing sizes
CDMO API
Back
CDMO API
About CDMO API
Development services
Technical capabilities of R&D
Commercial manufacturing
RfQ and project management
CMO Drug product
Back
CMO Drug product
About CMO Drug product
Semi-Solids and Liquids
Oral Solids
Small Volume Parenterals
Packaging
Technology Transfer Services
Contact
Back
Contact
Contact Information
Contact Form
Fermion
Who we are
News
News
Solar energy for Fermion’s Hanko plant
We are proud to announce that a new solar energy park of approximately 1800 solar panels has been installed at the Fermion’s Hanko plant
Fermion increases manufacturing capacity for APIs at its Hanko site with new module
Season's greetings from Fermion president Arto Toivonen
Fermion scales up it's OEB5 micronization capabilities
Orion as a long term partner for production of hormonal gels – customer view
How to succeed in technology transfers for hormonal gels – 4 critical factors
Fermion increases manufacturing capacity for highly potent APIs at its Hanko site
Fermion has received fluticasone propionate CEP
Fermion has received fluticasone propionate CEP
Green chemistry strengthens Orion's environmental responsibility
Green chemistry strengthens Orion's environmental responsibility
Fermion's mother company Orion Corporation wins CMO leadership awards in the category of expertise
Fermion's mother company Orion Corporation wins CMO leadership awards in the category of expertise
Fermion's long term customer G1 Therapeutics received FDA approval for COSELA™ (Trilaciclib)
Fermion's long term customer G1 Therapeutics received FDA approval for COSELA™ (Trilaciclib)
Orion uses waste ethanol to reduce the nitrogen load in the Baltic Sea
Orion uses waste ethanol to reduce the nitrogen load in the Baltic Sea
Load more